QuantLogix ← BMY scorecard
📅 BMY Earnings Preview
Bristol-Myers Squibb Co.
Next report (est.)
April 28, 2026
Countdown
Imminent
EPS growth YoY
+1225.0%
Revenue growth YoY
+1.3%
Options-implied earnings move
±2.7%
The at-the-money straddle prices a move to roughly $58.66 or $55.60 from $57.13 by June 18, 2026.
Implied vs actual — last 7 reports
ReportOptions impliedActual moveMarket was
October 30, 2025 ±1.5% +7.1% under-priced
July 31, 2025 ±2.7% -5.8% under-priced
April 24, 2025 ±3.1% +0.3% over-priced
October 31, 2024 ±1.7% +5.9% under-priced
April 25, 2024 ±1.4% -8.5% under-priced
October 26, 2023 ±1.6% -6.4% under-priced
July 27, 2023 ±1.8% -4.2% under-priced
Across these reports, options implied an average ±2.0% move vs an actual average of 5.5% — the stock stayed inside the implied band 14% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q4 FY2025 $0.53 $12.5B $1.1B
Q3 FY2025 $1.08 $12.2B $2.2B
Q2 FY2025 $0.64 $12.3B $1.3B
Q1 FY2025 $1.20 $11.2B $2.5B
Analyst posture
Buy / Strong Buy
14
Hold
20
Sell
2
Stable: -1 net change 30d
Live 5-factor engine read: Buy · 63/100 Full scorecard →
Get alerted before every BMY report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on BMY before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Bristol-Myers Squibb Co. (BMY) reports imminently, with the next report estimated for April 28, 2026. Across the last 7 reports, options priced an average ±2.0% earnings move while the stock actually moved 5.5% on average — the market has tended to under-price BMY's earnings risk. Fundamentals into the print: EPS up 1225.0% year-over-year, revenue up 1.3%. QuantLogix's live 5-factor engine currently reads BMY as a buy at 63/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →